Dietary HDAC inhibitors: Time to rethink weak ligands in cancer chemoprevention?

Carcinogenesis

Volumn 27, Issue 2, 2006, Pages 344-349

  Dashwood, Roderick H ^a,b   Myzak, Melinda C ^a,b   Ho, Emily ^a,b  

^a OREGON STATE UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 CIS RETINAL; 4 (METHYLSULFINYL) 3 BUTENYLISOTHIOCYANATE; ALITRETINOIN; ALLYLMERCAPTOCYSTEINE; ALPHA TOCOPHEROL; BIOTIN; BUTYRIC ACID; CYSTEINE DERIVATIVE; DIALLYL DISULFIDE; DITHIOCARBAMIC ACID; GAMMA TOCOPHEROL; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; ISOTHIOCYANIC ACID DERIVATIVE; LINOLEIC ACID; MONOERUCIN; PHENETHYL ISOTHIOCYANATE; PHENYLBUTYL ISOTHIOCYANATE; PROTEIN BAX; PROTEIN P21; RETINOIC ACID; SULFORAPHANE; SULFORAPHANE N ACETYLCYSTEINE; SULFORAPHANECYSTEINE; SULFORAPHANEGLUTATHIONE; THEOPHYLLINE; THIOCTIC ACID; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER PREVENTION; CELL CYCLE; CELL TRANSFORMATION; CHEMOPROPHYLAXIS; CHEMOSENSITIVITY; CHROMATIN ASSEMBLY AND DISASSEMBLY; DRUG RESEARCH; DRUG SELECTIVITY; ENZYME REGULATION; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW;

APOPTOSIS; CELL CYCLE; CHEMOPREVENTION; CHROMATIN ASSEMBLY AND DISASSEMBLY; DIET; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; LIGANDS;

EID: 31544436888     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgi253     Document Type: Review

References (47)

1. Szyf,M. (2005) DNA methylation and demethylation as targets for anticancer therapy. Biochemistry (Mosc)., 70, 533-549.
2. Cosgrove,M.S. and Wolberger,C. (2005) How does the histone code work? Biochem. Cell Biol., 83, 468-476.
3. Fraga,M.F., Ballestar,E., Villar-Garea,A. et al. (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet., 37, 391-400.
4. Allison,S.J. and Milner,J. (2004) Remodelling chromatin on a global scale: A novel protective function of p53. Carcinogenesis, 25, 1551-1557.
5. de Ruijter,A.J., van Gennip, A.H., Caron, H.N Stephan Kemp, and Andre B.P. Van Kuilenburg (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J., 370, 737-749.
6. Finnin,M.S., Donigian,J.R., Cohen,A., Richon,V.M., Rifkind,R.A., Marks,P.A., Breslow,R. and Pavletich,N.P. (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature, 401, 188-193.
7. Mork,C.N., Faller,D.V. and Spanjaard,R.A. (2005) A mechanistic approach to anticancer therapy: Targeting the cell cycle with histone deacetylase inhibitors. Curr. Pharm. Des., 11, 1091-1104.
8. McLaughlin,F. and La Thangue,N.B. (2004) Histone deacetylase inhibitors open new doors in cancer therapy. Biochem. Pharmacol., 68, 1139-1144.
9. Rosato,R.R. and Grant,S. (2003) Histone deacetylase inhibitors in cancer therapy. Cancer Biol. Ther., 2, 30-37.
10. Furumai,R., Komatsu,Y., Nishino,N., Khochbin,S., Yoshida,M. and Horinouchi,S. (2001) Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl Acad. Sci. USA, 98, 87-92.
11. Altucci,L. and Gronemeyer,H. (2001) The promise of retinoids to fight against cancer. Nat. Rev. Cancer, 1, 181-193.
12. Clarke,N., Germain,P., Altucci,L. and Gronemeyer,H. (2004) Retinoids: potential in cancer prevention and therapy. Expert Rev. Mol. Med., 6, 1-23.
13. Fazi,F., Travaglini,L., Carotti,D. et al. (2005) Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo. Oncogene, 24, 1820-1830.
14. Lin,R.J., Nagy,L., Inoue,S., Shao,W., Miller,W.H.,Jr. and Evans,R.M. (1998) Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature, 391, 811-814.
15. Grignani,F., De Matteis,S., Nervi,C. et al. (1998) Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature, 391, 815-818.
16. Emionite,L., Galmozzi,F., Grattarola,M., Boccardo,F., Vergani,L. and Toma,S. (2004) Histone deacetylase inhibitors enhance retinoid response in human breast cancer cell lines. Anticancer Res., 24, 4019-4024.
17. Cote,S., Rosenauer,A., Bianchini,A., Seiter,K., Vandewiele,J., Nervi,C. and Miller,W.H.,Jr. (2002) Response to histone deacetylase inhibition of novel PML/RAR-α mutants detected in retinoic acid-resistant APL cells. Blood, 100, 2586-2596.
18. He,L.Z., Tolentino,T., Grayson,P., Zhong,S., Warrell,R.P.,Jr., Rifkind,R.A., Marks,P.A., Richon,V.M. and Pandolfi,P.P. (2001) Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest., 108, 1321-1330.
19. Coffey,D.C., Kutko,M.C., Glick,R.D., Butler,L.M., Heller,G., Rifkind,R.A., Marks,P.A., Richon,V.M. and La Quaglia,M.P. (2001) The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res., 61, 3591-3594.
20. Taddei,A., Roche,D., Bickmore,W.A. and Almouzni,G. (2005) The effects of histone deacetylase inhibitors on heterochromatin: Implications for anticancer therapy? EMBO Rep., 6, 520-524.
21. Ungerstedt,J.S., Sowa,Y., Xu,W.S., Shao,Y., Dokmanovic,M., Perez,G., Ngo,L., Holmgren,A., Jiang,X. and Marks,P.A. (2005) Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA, 102, 673-678.
22. Nebbioso,A., Clarke,N., Voltz,E. et al. (2005) Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med., 11, 77-84.
23. Myzak,M.C. and Dashwood,R.H. (2006) Histone deacetylases as targets for dietary cancer preventive agents: Lessons learned with butyrate, diallyl disulfide, and sulforaphane. Current Drug Targets, in press.
24. Cummings,J.H., Pomare,E.W., Branch,W.J., Naylor,C.P. and Macfarlane,G.T. (1987) Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut, 28, 1221-1227.
25. Bach Knudsen,K.E., Serena,A., Canibe,N. and Juntunen,K.S. (2003) New insight into butyrate metabolism. Proc. Nutr. Soc., 62, 81-86.
26. McIntosh,G.H., Royal,P.J. and Pointing,G. (2001) Wheat aleurone flour increases cecal β-glucuronidase activity and butyrate concentration and reduces colon adenoma burden in azoxymethane-treated rats. J. Nutr., 131, 127-131.
27. Bach Knudsen,K.E., Serena,A., Kjaer,A.K., Jorgensen,H. and Engberg,R. (2005) Rye bread enhances the production and plasma concentration of butyrate but not the plasma concentrations of glucose and insulin. J. Nutr., 135, 1696-1704.
28. waf1/cip1 expression in human colon cancer cell lines. Carcinogenesis, 25, 1227-1236.
29. Guyonnet,D., Berges,R., Siess,M.H., Pinnert,M.F., Chagnon,M.C., Suschetet,M. and Le Bon,A.M. (2004) Post-initiation modulating effects of allyl sulfides in rat hepatocarcinogenesis. Food Chem. Toxicol., 42, 1479-1485.
30. Myzak,M.C., Karplus,P.A., Chung,F.L. and Dashwood,R.H. (2004) A novel mechanism of chemoprotection by sulforaphane: Inhibition of histone deacetylase. Cancer Res., 64, 5767-5774.
31. Ye,L., Dinkova-Kostova,A.T., Wade,K.L., Zhang,Y., Shapiro,T.A. and Talalay,P. (2002) Quantitative determination of dithiocarbamates in human plasma, serum, erythrocytes and urine: Pharmacokinetics of broccoli sprout isothiocyanates in humans. Clin. Chim. Acta., 316, 43-53.
32. Bianchini, F and Vainio H. (2004) Isothiocyanates in cancer prevention. Drug Metab. Rev., 36, 655-667.
33. Keum,Y.S., Jeong,W.S. and Kong,A.N. (2004) Chemoprevention by isothiocyanates and their underlying molecular signaling mechanisms. Mutat. Res., 555, 191-202.
34. Knowles,L.M. and Milner,J.A. (2001) Possible mechanisms by which allyl sulfides suppress neoplastic cell proliferation. J. Nutr., 131, 1061s-1066s.
35. CIP1 and inhibition of expression of cyclin D1. Cancer Chemother Pharmacol, Sep 17, 1-11 [Epub ahead of print].
36. Singh,S.V., Srivastava,S.K., Choi,S. et al. (2005) Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species. J. Biol. Chem., 280, 19911-19924.
37. Kang,J., Zhang,Y., Chen,Y., Chen,H., Lin,C., Wang,Q. and Ou,Y. (2003) Nickel-induced histone hypoacetylation: The role of reactive oxygen species. Toxicol. Sci., 74, 279-286.
38. Kang,J., Chen,J., Zhang,D., Da,W. and Ou,Y. (2004) Synergistic killing of human leukemia cells by antioxidants and trichostatin A. Cancer Chemother Pharmacol, 54, 537-545.
39. Pariza,M.W. (2004) Perspectives on the safety and effectiveness of conjugated linoleic acid. Am. J. Clin. Nutr., 79, 1132s-1136s.
40. Suh,J.H., Shenvi,S.V., Dixon,B.M. Liu,H., Jaiswal,A.K., Liu,R.M., Hagen,T.M. (2004) Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc. Natl Acad. Sci. USA, 101, 3381-3386.
41. Sontag,T.J. and Parker,R.S. (2002) Cytochrome P450 ω-hydroxylase pathway of tocopherol catabolism. J. Biol. Chem., 277, 25290-25296.
42. Birringer,M., Pfluger,P., Kluth,D., Landes,N. and Brigelius-Flohe,R. (2002) Identities and differences in the metabolism of tocotrienols and tocopherols in HepG2 cells. J. Nutr., 123, 3113-3118.
43. Cosio,B.G., Tsaprouni,L., Ito,K., Jazrawi,E., Adcock,I.M. and Barnes,P.J. (2004) Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J. Exp. Med., 200, 689-695.
44. Borra,M.T., Smith,B.C. and Denu,J.M. (2005) Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem., 280, 17187-17195.
45. Pauling,L. (1968) Orthomolecular psychiatry. Varying the concentrations of substances normally present in the human body may control mental disease. Science, 160, 265-271.
46. Gonzalez,M.J., Miranda-Massari,J.R., Mora,E.M., Guzman,A., Riordan,N.H., Riordan,H.D., Casciari,J.J., Jackson,J.A. and Roman-Franco,A. (2005) Orthomolecular oncology review: Ascorbic acid and cancer 25 years later. Integr. Cancer Ther., 4, 32-44.
47. INK4a, RARß, and MGMT genes by genistein and other isoflavones from soy. Clin. Cancer Res., 11, 7033-7041.